Up 200% in 6 months, guess which ASX All Ords stock just hit another all-time high

This All Ords stock has made its investors very rich in recent months…

| More on:
Lab worker puts hands in the air and dances around

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One ASX All Ordinaries Index (ASX: XAO) stock has returned more than 200% to its investors over the past six months alone. Today, it celebrated a second feat by hitting another new all-time high.

Which ASX All Ords company? That would be Clarity Pharmaceuticals Ltd (ASX: CU6). Yes, it was only in early November last year that Clarity shares were trading at $1.06 each. Today, those same shares will set an investor back $3.27.

As mentioned, this Thursday also saw Clarity hit a new record high. Just after the market opened this morning, the All Ords pharmaceutical stock hit $3.31, its new all-time record.

Why has this ASX All Ords stock just hit a new record high?

Here at the Motley Fool, we've been tracking Clarity's rising star over most of the year. Back in January, my Fool colleague analysed Frazis Capital portfolio manager Michael Frazis's view on the company.

Frazis presciently called Clarity "the most exciting company I've come across in Australia lately", thanks to the favourable data surrounding its copper therapy treatment for late-stage prostate cancer.

Frazis also argued that the company remained vastly undervalued compared to its potential:

If their data continues to hold, this is still early days, and it remains a fraction of the value of recent acquisitions in the space with early stage data.

In March, we also discussed ASX broker Bell Potter's optimistic view on Clarity Pharmaceuticals. Bell Potter posited similar sentiments to Frazis, noting Clarity's prostate cancer patient's having "apparently with no disease progression, many months after commencing treatment".

At the time, Bell Potter gave the All Ords stock a 'speculative buy' rating alongside a share price target of $3.25. That target has certainly aged well.

It was only earlier this week that Clarity revealed its first patient to be dosed with two cycles of its treatment achieved "a complete response", with "undetectable levels of prostate specific antigen (PSA) for almost 6 months".

Much of Clarity's share price gains have come since this positive announcement. Since Monday this week, this ASX All Ords stock has gained a whopping 26.4%. Let's see where this exciting company is headed next.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

Buy, hold or sell these 3 ASX 200 healthcare shares: Experts

These experts reveal their calls on CSL, Resmed and Sonic Healthcare shares today.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Share Gainers

Guess which ASX healthcare stock just exploded 63% on Federal budget funding news!

Investors are bidding up the ASX healthcare stock amid extra funding in the Federal budget.

Read more »

two doctors smile as they sit together at a desk looking at a patient's Xray.
Healthcare Shares

This ASX 200 healthcare stock just hit an all-time high: Is it too late to buy?

The valuation of this high-performer has soared.

Read more »

A smiling woman sits in a cafe reading a story on her phone about Rio Tinto and drinking a coffee with a laptop open in front of her.
Healthcare Shares

1 magnificent ASX stock down 10% to buy and hold forever

Analysts say this high-quality stock is a great option for investors right now.

Read more »

ventilator mask
Healthcare Shares

3 reasons ResMed shares 'are just too cheap!'

This stock could still produce healthy gains, according to one fund manager.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

2 ASX healthcare shares rocking higher on big news

This 'spray-on skin' company and cancer-fighting biotech have exciting news for shareholders today.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Insider still buying Mesoblast shares despite 230% rise this year: Should you buy?

This high-flying share is still reporting insider buying. Should you buy too?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Buy CSL shares for growing dividends and 'compelling long-term tailwinds'

CSL has increased both its interim and final dividend every year since 2021.

Read more »